Machine-learning technology developer Unlearn has raised $50m in a Series B financing round led by US-based global venture capital and private equity firm Insight Partners to advance the use of TwinRCTs in clinical trials.
New investor Radical Ventures and current investors of the company, including DCVC, 8VC, Mubadala Capital Ventures and DCVC Bio, took part in the funding round.
Unlearn intends to use the proceeds to progress the usage of its machine learning-powered twinRCTs in trials.
The company collaborates with biotech firms, pharma sponsors and academic institutes to streamline human clinical trials with TwinRCTs.
A randomised trial, TwinRCT leverages machine learning and historical data to attain an increased chance of success with a smaller number of patients.
In TwinRCTs, participants are assigned to treatment and control arms similar to a standard randomised controlled trial (RCT), but a digital twin is calculated for each patient utilising a machine learning model trained on historical control data compared to the traditional RCT.
After modifying the prognostic score for each patient obtained from their digital twin, the treatment impacts for the primary and secondary outcomes can be calculated with increased precision.
As part of the financing, Insight Partners managing director Dylan Morris joined Unlearn’s board of directors.
Unlearn founder and CEO Charles Fisher said: “Unlearn continues to make rapid progress as we expand our work with global biopharmaceutical companies and advance productive conversations with global regulatory authorities who are committed to supporting innovation in clinical trials.
“This new financing is validation of our expanding footprint in clinical trials.”
In February this year, the company signed a multi-year partnership with Merck KGaA, Darmstadt, Germany, which is leveraging TwinRCTs to integrate predictive information from digital twins into its randomised controlled trials.